Hotsia.Com : เที่ยวสะใจ

How does SGLT2 + ACEi/ARB combination impact albuminuria vs monotherapy, what outcome trials show, and how does this compare with finerenone add-on?

Combining an SGLT2 inhibitor with an ACEi or ARB has a synergistic and more pronounced impact on reducing albuminuria compared to using either drug alone. This enhanced effect stems from their complementary mechanisms of action, which target different pathways contributing to kidney damage and protein leakage. ACEi/ARBs primarily reduce glomerular pressure by dilating the efferent arteriole, while SGLT2 inhibitors constrict the afferent arteriole, creating a powerful, additive effect that significantly lowers the pressure within the glomerulus. This dual action reduces the mechanical stress on the delicate filtration barrier, thereby decreasing albuminuria. Additionally, SGLT2 inhibitors provide benefits independent of blood pressure, such as reducing inflammation, fibrosis, and oxidative stress, which further protects the kidneys and contributes to the reduction in albuminuria. The combination therapy therefore not only offers a powerful hemodynamic effect but also provides comprehensive renoprotection.

📉 Outcome Trials and Evidence

The clinical evidence supporting the combination of SGLT2 inhibitors and ACEi/ARBs is robust and comes from large-scale, landmark outcome trials. In these trials, SGLT2 inhibitors were typically added to a standard of care that already included an ACEi or ARB. The results from trials like CREDENCE, DAPA-CKD, and EMPA-KIDNEY demonstrated a significant and consistent reduction in kidney-related composite endpoints, including a substantial decrease in albuminuria. For example, in the DAPA-CKD trial, dapagliflozin significantly reduced the risk of a composite kidney outcome by 39% compared to placebo, with a pronounced reduction in the urinary albumin-to-creatinine ratio (UACR). A similar effect was seen in the CREDENCE trial with canagliflozin. These trials have shown that the combination therapy not only slows the progression of chronic kidney disease (CKD) but also provides cardiovascular benefits, such as a reduced risk of heart failure and cardiovascular death. The consistent finding across these studies is that adding an SGLT2 inhibitor to an already optimized ACEi/ARB regimen provides substantial and clinically meaningful benefits, which is a major paradigm shift in the management of CKD. This body of evidence has led to global guideline updates recommending the use of SGLT2 inhibitors on top of ACEi/ARBs in patients with CKD, particularly those with type 2 diabetes and albuminuria.

🆚 SGLT2 + ACEi/ARB vs. Finerenone Add-On

While both the SGLT2 inhibitor + ACEi/ARB combination and the finerenone add-on therapy are highly effective at reducing albuminuria and protecting the kidneys, they work through different mechanisms and have distinct clinical profiles. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA). It works by blocking the mineralocorticoid receptor, thereby reducing inflammation and fibrosis in the kidneys and heart, which are key drivers of kidney disease progression. Unlike older steroidal MRAs (like spironolactone), finerenone has a much lower risk of hyperkalemia and is a safer option for CKD patients. The landmark FIDELIO-DKD and FIGARO-DKD trials showed that finerenone, when added to an ACEi or ARB, significantly reduced the risk of kidney failure and cardiovascular events in patients with diabetic kidney disease. This makes finerenone another pillar of cardiorenal protection.

The key difference lies in the synergistic effect. While a combination of SGLT2 inhibitor and ACEi/ARB provides both a powerful hemodynamic effect (by reducing glomerular pressure) and an anti-inflammatory/anti-fibrotic effect, finerenone primarily targets the latter. SGLT2 inhibitors and finerenone are not mutually exclusive; in fact, they are now often used together in a “quad therapy” regimen with an ACEi/ARB and a GLP-1 receptor agonist. Emerging data, including a sub-analysis from a finerenone trial, suggests that adding finerenone to a regimen that already includes an SGLT2 inhibitor provides additional benefits in reducing albuminuria and improving cardiorenal outcomes, with the SGLT2 inhibitor potentially mitigating the risk of hyperkalemia associated with finerenone. Therefore, they are considered complementary, not competing, therapies. The choice between them as a second-line add-on to ACEi/ARB therapy often depends on a patient’s specific clinical picture, including their glycemic control, heart failure status, and risk of hyperkalemia, but increasingly, guidelines recommend using both to achieve maximum cardiorenal protection.

 

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com